Development of United States Guidelines for the Diagnosis and Treatment of Adults With ADHD: October 2023 healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Tris Pharma, Inc. ("Tris"), an innovative and fully integrated pharmaceutical company with a robust portfolio of approved products for the.
APSARD and Tris Pharma Announce the 2021 Tris Research Award in ADHD
News provided by
Share this article
Share this article
MONMOUTH JUNCTION, N.J., Jan. 28, 2021 /PRNewswire/ The American Professional Society of ADHD and Related Disorders ( APSARD ), a professional organization focused on improving outcomes for individuals with ADHD and their families, and Tris Pharma, Inc. ( Tris ), a specialty pharmaceutical company with a robust portfolio of approved products for the treatment of Attention Deficit Hyperactivity Disorder, have jointly announced the 2021 recipients of a multi-year research award to advance and recognize outstanding research in the field of ADHD.
The Tris Research Award recognizes innovative research that facilitates a better understanding of the diagnosis, recognition and/or treatment of ADHD and related disorders. APSARD is solely responsible for the management, decision making and oversight of this award. The 2021 recipients of the award, independently